Welchol: Phase IV data

In a double-blind, international Phase IV trial in 286 treatment-naive Type II diabetics, 3.75 g/day Welchol plus metformin met the primary endpoint of significantly reducing mean HbA1c from baseline to week 16 vs. placebo plus metformin (1.1% vs. 0.8%, p<0.01). On secondary endpoints, a significantly greater proportion of patients treated with Welchol plus metformin achieved HbA1c <7% (67% vs. 56%, p<0.01) and LDL cholesterol <100 mg/dL (48% vs. 18%, p<0.0001) vs. metformin alone. ...